The stock has a 36-month beta value of 1.95. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for SLRN is 73.18M, and at present, short sellers hold a 7.81% of that float. On December 20, 2024, the average trading volume of SLRN was 680.79K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SLRN) stock’s latest price update
The stock price of Acelyrin Inc (NASDAQ: SLRN) has plunged by -1.40 when compared to previous closing price of 3.22, but the company has seen a -1.70% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-10 that Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance
SLRN’s Market Performance
Acelyrin Inc (SLRN) has experienced a -1.70% fall in stock performance for the past week, with a -28.33% drop in the past month, and a -35.73% drop in the past quarter. The volatility ratio for the week is 10.73%, and the volatility levels for the past 30 days are at 8.26% for SLRN. The simple moving average for the last 20 days is -20.35% for SLRN stock, with a simple moving average of -38.35% for the last 200 days.
Analysts’ Opinion of SLRN
Many brokerage firms have already submitted their reports for SLRN stocks, with H.C. Wainwright repeating the rating for SLRN by listing it as a “Neutral.” The predicted price for SLRN in the upcoming period, according to H.C. Wainwright is $6 based on the research report published on August 14, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see SLRN reach a price target of $13. The rating they have provided for SLRN stocks is “Overweight” according to the report published on July 08th, 2024.
Wells Fargo gave a rating of “Equal Weight” to SLRN, setting the target price at $11 in the report published on December 13th of the previous year.
SLRN Trading at -36.80% from the 50-Day Moving Average
After a stumble in the market that brought SLRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.27% of loss for the given period.
Volatility was left at 8.26%, however, over the last 30 days, the volatility rate increased by 10.73%, as shares sank -27.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.39% lower at present.
During the last 5 trading sessions, SLRN fell by -2.79%, which changed the moving average for the period of 200-days by -62.66% in comparison to the 20-day moving average, which settled at $3.98. In addition, Acelyrin Inc saw -57.44% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SLRN starting from Becker Daniel J., who sale 1 shares at the price of $6.86 back on Jul 17 ’24. After this action, Becker Daniel J. now owns 2,999 shares of Acelyrin Inc, valued at $7 using the latest closing price.
Lin Shao-Lee, the Chief Executive Officer of Acelyrin Inc, sale 9,961 shares at $6.63 during a trade that took place back on Apr 01 ’24, which means that Lin Shao-Lee is holding 1,577,374 shares at $66,024 based on the most recent closing price.
Stock Fundamentals for SLRN
Current profitability levels for the company are sitting at:
- -2022.04 for the present operating margin
- -0.32 for the gross margin
The net margin for Acelyrin Inc stands at -1592.8. The total capital return value is set at -0.63. Equity return is now at value -41.95, with -37.27 for asset returns.
Currently, EBITDA for the company is -381.53 million with net debt to EBITDA at 0.64. When we switch over and look at the enterprise to sales, we see a ratio of 652.19. The receivables turnover for the company is 0.01for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.15.
Conclusion
To sum up, Acelyrin Inc (SLRN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
